Aurinia Pharmaceuticals Inc. (AUPH) — closed signal from July 11, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on October 9, 2025.
Predicted vs. what happened
What happened
Reached its target in 35 days.
The thesis — published July 11, 2025
Early study results for AUR200 looked good, and trading volume was triple normal as the price jumped above its long-term average, showing strong interest. Cash from Lupkynis pays the bills, so new share sales seem unlikely for now. TD Cowen kept an 11-dollar goal after the June 30 news. Similar biotech rallies average 40 % in three months, pointing to a possible climb toward 13 dollars.
Primary drivers
- Strong early AUR200 results lower scientific risk and could widen the patient group
- Triple normal trading volume shows big investors are likely joining the move upward
- Cash from Lupkynis sales helps fund research, so fewer new shares should be needed
- TD Cowens 11 dollar goal gives an easy reference point for near term price hopes
How it played out
AUPH: target reached in 35 days
Lyra published AUPH at $8.93 on 2025-07-11 with a short-term thesis for 38% expected growth. The thesis pointed to early AUR200 study results, triple normal trading volume, cash from Lupkynis sales, and TD Cowen's 11 dollar goal after the June 30 news.
Inside the window from 2025-07-11 to 2025-10-09, the stock reached the $12.32 target in 35 days. It later peaked at $13.54 on 2025-09-29, with a 51.6% peak gain. It ended at $11.62, below the peak but still above the publication price. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.